Can ImmunityBio (IBRX) Stock Reach $16?

Key Takeaways

• The $16 central target is the arithmetic mean of five verified analyst price targets, which span a wide $12 to $23 range.
• The four most recently updated targets (all October 2026) average about $14.25, while D. Boral Capital's $23 stands well above the rest.
• At a recent price near $9.18, reaching $16 would require a gain of roughly 74% — a very large move by any standard.
• Bullish support rests on ANKTIVA's expanded FDA approval and sharply accelerating revenue; the biggest risks are execution, competition, and persistent losses.

Analyst Price Targets and Consensus View

ImmunityBio, Inc. (IBRX) is a clinical-stage biotechnology company developing immunotherapies that activate the immune system against cancer and infectious diseases. Five attributable analyst price targets were reviewed to build the central target: BTIG ($12, Buy), Jefferies ($14, Buy), H.C. Wainwright ($15, Buy), Piper Sandler ($16, Overweight), and D. Boral Capital ($23, Buy). Their arithmetic mean is $16.00, which becomes the central target.

The range is unusually wide at $12 to $23, reflecting genuine disagreement about how quickly ANKTIVA's commercial ramp translates into value. On October 14, 2026, both Piper Sandler (raising to $16 from $12) and Jefferies (raising to $14 from $12) lifted targets after the FDA expanded ANKTIVA's approval into BCG-unresponsive non-muscle invasive bladder cancer with papillary-only tumors. D. Boral Capital's $23 target, last reaffirmed in April 2026, sits materially above the consensus cluster; excluding it, the four October targets average $14.25. The overall rating picture is strongly constructive, with every tracked firm at Buy or Overweight and no Hold or Sell ratings in the current set.

Current Market Position and Path Toward the Target

IBRX last closed near $9.18, down from roughly $9.91 earlier in the week and below its 52-week high of about $12.43. From $9.18, a move to the $16 target implies upside of approximately 74%, which must be described as a very large required move. The stock has already delivered an extraordinary run, more than tripling over the trailing year as investors repriced ANKTIVA's commercial potential.

The path toward $16 would likely depend on continued revenue acceleration rather than further valuation expansion alone. Full-year 2025 ANKTIVA net revenue grew about 700% to roughly $113 million, and consensus forecasts project revenue near $227 million for 2026 and roughly $472 million for 2027. Because the company remains unprofitable — reporting significant GAAP net losses in recent quarters — the stock trades on revenue growth, pipeline optionality, and label-expansion momentum rather than earnings multiples.

What Could Support a Move Toward the Target

• Expanded label: The October 2026 FDA expansion into papillary-only tumors widens ANKTIVA's addressable patient population, the direct catalyst behind the latest target increases.
• Revenue momentum: Triple-digit revenue growth and projected near-doubling of sales in 2026 and 2027 support the bull case.
• Pipeline optionality: Additional ANKTIVA studies in new settings could further expand the opportunity and justify higher targets.
• Analyst revisions: Targets have been rising through 2026, and further upgrades would reinforce upward pressure on the stock forecast.

What Could Prevent the Target From Being Reached

• Persistent losses: Large GAAP net losses and negative EPS (earnings per share) mean the stock lacks earnings-based valuation support.
• Execution risk: A slower-than-expected commercial ramp or disappointing trial readouts in new settings could compress the multiple.
• Competition: The bladder-cancer immunotherapy market is contested, and rival therapies could limit share gains.
• Valuation and volatility: After a very sharp rally, the stock is prone to sharp pullbacks — as seen in the recent single-day decline — and a high target like $23 signals elevated expectations.

Technical Levels and Market Structure

The 52-week range of roughly $1.95 to $12.43 frames the stock's extraordinary climb. The $12.43 area represents the most meaningful resistance level, as it marks the prior high and sits above the current price; the stock would need to reclaim and hold that zone before $16 becomes a realistic technical objective. On the downside, round-number support near $9 and the mid-single-digit levels offer reference points if momentum fades. The long-term trend remains strongly upward, but the gap between the current price and the 52-week high underscores how much of the move has already occurred.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual firms apply different assumptions about revenue growth, discount rates, and pipeline probability. The wide $12-to-$23 range reflects that divergence rather than a single shared timeline. Investors should monitor upcoming quarterly earnings and revenue updates, any additional FDA or regulatory developments for ANKTIVA, new trial data, and changes to analyst price targets, all of which could shift the consensus materially given the stock's volatility.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like IBRX, these signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual chart-watching. Explore the tool to bring automated, data-driven signal monitoring to your own market workflow.

Final Assessment

Can ImmunityBio stock reach $16? The target, derived as the mean of five verified analyst price targets ranging from $12 to $23, sits roughly 74% above the recent price near $9.18, making it a very large required move. The strongest supports are ANKTIVA's expanded approval, accelerating revenue, and a uniformly bullish analyst stance; the principal obstacles are continued losses, execution risk, competition, and a stretched valuation after a massive rally. With analysts clustered between $12 and $16 and one $23 outlier, disagreement centers on pace rather than direction. Whether $16 is reached will hinge on revenue execution and further pipeline or label catalysts, not on the target itself — and no analyst target is a guarantee of future performance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations